Table 1.
Summary of the publications included in this meta-analysis
Study | Country | Specimen | Method | Cancer type | Case | Control | miRNA profiling | Sensitivity (%) | Specificity (%) | QUADAS score |
---|---|---|---|---|---|---|---|---|---|---|
Mengual et al21 | Spain | Voided urine | qRT-PCR | UCC | 181 | 136 | miR-187, miR-140-5p, miR-18a, miR-25, miR-204, and miR-142-3p | 84.8 | 86.5 | 8 |
Miah et al20 | UK | Urine sediment | RT-PCR | UCC | 68 | 53 | miR-15a | 51.7 | 72 | 7 |
miR-15b | 67.8 | 81.3 | ||||||||
miR-24-1 | 60 | 58.5 | ||||||||
miR-27b | 60.3 | 81.1 | ||||||||
miR-100 | 60.4 | 78.7 | ||||||||
miR-135b | 71.2 | 74.4 | ||||||||
miR-203 | 66.1 | 66 | ||||||||
miR-212 | 54.2 | 64 | ||||||||
miR-328 | 55.4 | 86.8 | ||||||||
miR-1224 | 75.9 | 82.4 | ||||||||
Combination of miRs 135b/15b/1224-3p |
94.5 | 51 | ||||||||
Yamada et al18 | Japan | Urine sediment | RT-PCR | UC | 100 | 74 | miR-96 | 71 | 89.2 | 5 |
miR-183 | 74 | 77.3 | ||||||||
Hanke et al8 | Germany | Voided urine | RT-PCR | BCa | 18 | 18 | miR-126:miR-152 | 72 | 82 | 7 |
Snowdon et al10 | USA | Voided urine | qRT-PCR | UC | 8 | 5 | miR-125b,miR-126 | 80 | 100 | 9 |
Yun et al17 | Korea | Urine supernatant | RT- PCR | TCC | 207 | 144 | miR-145 | 77.8 | 61.1 | 7 |
Zhang et al16 | People’s Republic of China | Urine supernatant | qRT-PCR | UCB | 50 | 21 | miR-99a and miR-125b | 90 | 90 | 9 |
miR-99a | 78 | 85.7 | ||||||||
miR-125b | 84.8 | 76.2 | ||||||||
Wang et al9 | People’s Republic of China | Urine sediment | qRT-PCR | BCa | 51 | 24 | miR-200a | 100 | 52.6 | 9 |
Tölle et al19 | Germany | Voided urine | qRT-PCR | BCa | 36 | 19 | miR-1255b-5p | 85 | 68.4 | 9 |
miR-618 | 70 | 68.4 |
Note: All miRNAs are determined at a statically significant level (P<0.05).
Abbreviations: miRNA, microRNA; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RT-PCR, real-time polymerase chain reaction; UCC, urothelial cell carcinoma; BCa, bladder cancer; UC, urothelial carcinoma; UCB, urothelial carcinoma of the bladder; TCC, transitional cell carcinoma; QUADAS, Quality Assessment of Diagnostic Accuracy Studies.